Antiretroviral Therapy (ART)

DRUG11 trials

Conditions

ANTIRETROVIRAL TREATMENTAcquired Immunodeficiency SyndromeHIVHIV InfectionHIV InfectionsHIV-1 InfectionHIV-1-infectionHIV/AIDS

Phase 1

Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

WithdrawnNCT05769569

Henry M. Jackson Foundation for the Advancement of Military MedicineHIV-1-infection

Start: 2023-09-01End: 2025-07-01Updated: 2024-05-03

Phase 2

Aspirin and Antiretroviral Therapy in HIV Infected Patients

TerminatedNCT00783614

Hennepin Healthcare Research InstituteHIV Infection

Start: 2008-10-31End: 2010-06-30Updated: 2017-11-21

Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy

CompletedNCT02489461

ViriomHIV-1-infection

Start: 2014-08-05End: 2017-09-18Updated: 2018-09-25

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

WithdrawnNCT04041362

United BioPharmaHIV-1 Infection

Start: 2020-04-30End: 2021-03-31Updated: 2020-02-21

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

TerminatedNCT04272242

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection, LTBI

Start: 2021-02-27End: 2021-12-27Updated: 2024-09-19

Baricitinib Curative Repression of HIV-1

Not yet recruitingNCT07209267

Emory UniversityHIV, HIV Infection

Start: 2026-09-01End: 2028-01-01Target: 35Updated: 2026-07-17

Phase 4

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

CompletedNCT01285050

Johns Hopkins UniversityHepatitis C, HIV Infection

Start: 2011-01-31End: 2015-04-30Updated: 2016-11-29

Unknown Phase

Understanding the Increased Risk of Cardiovascular Disease in People With HIV

CompletedNCT00577681

University of MinnesotaHIV Infections

Start: 2002-01-31End: 2006-01-31Updated: 2019-11-01

Immediate ART in Subjects With Opportunistic Diseases

CompletedNCT03825523

Gustavo Reyes-TeranANTIRETROVIRAL TREATMENT, HIV/AIDS

Start: 2018-01-29End: 2025-08-05Updated: 2026-06-30

Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency

Not yet recruitingNCT07698548

Beijing University of Chinese MedicineAcquired Immunodeficiency Syndrome, HIV-1 Infection, Immune Reconstitution Failure +2

Start: 2026-08-01End: 2029-02-01Target: 240Updated: 2026-07-13

Qiling Yiqi Tablets Plus Antiretroviral Therapy for HIV Immune Non-responders With Lung-Spleen Qi Deficiency

Not yet recruitingNCT07698574

Beijing University of Chinese MedicineAcquired Immunodeficiency Syndrome, HIV-1 Infection, Immune Reconstitution Failure +2

Start: 2026-08-01End: 2029-02-01Target: 240Updated: 2026-07-13

Related Papers

Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention

Clinical Infectious Diseases2024-04-035 citations

Decreased Activated CD4 <sup>+</sup> T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 <sup>+</sup> T Cell Recovery

Viral Immunology2021-10-212 citations

Presence of Human Hepegivirus-1 in a Cohort of People Who Inject Drugs.

2017-06-0629 citations

Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals.

2017-06-0113 citations